Hepatitis E Clinical Trial
Official title:
Safety and Immunogenicity Study of the Recombinant Hepatitis E Vaccine(Escherichia Coli) in Healthy Volunteers Aged Over 65 Years
Verified date | October 2015 |
Source | Xiamen Innovax Biotech Co., Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Food and Drug Administration |
Study type | Interventional |
This phase IV clinical study was designed to evaluate the safety and immunogenicity of the recombinant Hepatitis E vaccine(Hecolin®), manufactured by Xiamen Innovax Biotech CO., LTD., in healthy volunteers aged over 65 years of age at enrollment. The study volunteers will receive the 3 doses of Hecolin® administered intramuscularly according to a 0-1-6 month schedule.
Status | Completed |
Enrollment | 600 |
Est. completion date | May 2016 |
Est. primary completion date | May 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Healthy people aged over 18 years old on the day of enrollment 2. Axillary temperature is below than 37.0 ? 3. Blood pressure is not higher than 160/100 mmHg (with or without any medicine) 4. Judged as healthy and eligible for vaccination by the investigators through a self-reported medical history and some physical examinations. 5. Able to understand this study information and willing to comply with all study requirements. 6. Willing to participate in this study and sign informed consent form. Exclusion Criteria: 1. Participated in any other clinical trial during the study period. 2. Use of any investigational product or non-registered product (drug or vaccine) within 30 days preceding the first dose of the study vaccine or plan to use during the study period. 3. Received immunosuppressed, immunoregulation therapy or corticosteroid systemic therapy for more than 14 days in the 6 months before entry, except local treatment. 4. Administration of any immunoglobulin or blood products within 3 months preceding the first dose of the study vaccine,or plan to use during the study period. 5. Administration of any inactivated vaccines within 14 days preceding the first dose of the study or attenuated live vaccines within 21 days preceding the first dose of the study. 6. Had a fever (axillary temperature over 38°C) within 3 days or acute illness requiring systemic antibiotics or antiviral treatment within 5 days before vaccination. 7. Immunodeficiency (such as HIV carriers), primary disease of important organs, malignant tumor, .or any immune disease (such as systemic lupus erythematosus, arthritis pauperum, splenectomy or functional asplenia or other disease which might affect immune response). 8. History of allergic disease or history of serious adverse events occurring after vaccination, i.e., allergy,urticaria, dyspnea, angioneurotic edema or abdominal pain. 9. Pregnant or breastfeeding 10. Allergic history to any component of this vaccine. 11. Other medical, psychological, social or occupational factors that, according to the investigators' judgment,might affect the individual's ability to obey the protocol or sign the informed consent. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
China | Kaihua Center for Disease Control and Prevention | Quzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Xiamen Innovax Biotech Co., Ltd | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse reactions/events | Measure solicited local adverse reactions within 7 days after each vaccination; Measure solicited systematic adverse reactions within 7 days after each vaccination; Measure unsolicited adverse reactions within 30 days after vaccination; Measure serious adverse events occurred throughout the study | up to 10 months | Yes |
Secondary | Anti-HEV antibody | Measure anti-HEV antibody in serum samples at 7 month to evaluate the immunogenicity of the Hepatitis E vaccine. | 7 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03365921 -
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial)
|
Phase 4 | |
Completed |
NCT02584543 -
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)
|
Phase 4 | |
Not yet recruiting |
NCT03488589 -
HEV in Patients With Acute Non-A, Non-B, Non-C Hepatitis in Al-Rajhy University Hospital for Liver
|
||
Completed |
NCT03601221 -
Seroprevalence Hepatitis E Infection in Healthy Blood Donors
|
||
Completed |
NCT03168412 -
A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule)
|
Phase 4 | |
Completed |
NCT02189603 -
Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine(Hecolin®)
|
Phase 4 | |
Completed |
NCT02847507 -
Seroprevalence of Hepatitis E in HIV Positive Patients in Basque Country in 2016 (VIhVhEpb)
|
||
Completed |
NCT02603055 -
A Clinical Trial to Evaluate a Recombinant Hepatitis E Vaccine in Healthy Adults
|
Phase 1 | |
Completed |
NCT02190253 -
Seroprevalence of Hepatitis E in People With an Organ Transplant
|
||
Recruiting |
NCT06457438 -
Molecular Characteristics and Prevalence of Viral Hepatitis E in Human Tissue and Cell Donors
|
N/A | |
Completed |
NCT04670419 -
Morbidity and Mortality of Hepatitis E Virus Infections in Belgium
|
||
Completed |
NCT03282474 -
HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE)
|
Phase 2 | |
Terminated |
NCT02558114 -
Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection.
|
Phase 4 | |
Recruiting |
NCT06137313 -
Exposure to Hepatitis E Virus in Occitania, France
|
||
Completed |
NCT02964910 -
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )
|
Phase 4 | |
Completed |
NCT01014845 -
Clinical Trial of Recombinant Hepatitis E Vaccine
|
Phase 3 | |
Recruiting |
NCT05976594 -
Long-term Effectiveness of a Recombinant Hepatitis E Vaccine
|
||
Completed |
NCT03827395 -
Safety Study of Hepatitis E Vaccine (HEV239)
|
Phase 1 |